The suppression efficiency of Tregs on LLL12b-treated CD4+ Teffs was significantly higher than control-treated CD4+ Teffs (Figure 5M), suggesting that LLL12b may correct the defects of Treg resistance of CD4+ Teffs from MS patients, which may provide therapeutic benefit for MS patients. The gene discussed is CD4; the disease is myeloid sarcoma.